The major objective of this investigation is to conduct a multi-center, double-blinded randomized trial comparing the efficacy of two therapies for the prevention of recurrent spontaneous abortion (RSA): immunotherapy using paternal leukocytes combined with """"""""Tender Loving Care"""""""" (TLC) therapy versus TLC therapy alone. We propose to randomize 524 couples over four years. Couples meeting the following criteria will be included in this trial: l)greater than or equal to consecutive spontaneous abortions; 2) No more than one viable gestation (greater than or equal to 28 weeks gestation) in the first pregnancy only; 3) No maternal lymphocytotoxic antibodies (LCTA) or maternal serum blocking factors (BF); 4) No known cause of miscarriage (excluding cytogenetic, autoimmune, anatomic, infectious etiologies); 5) No contraindications for using husband's cells for immunization; and 6) No consanguinity between partners or increased risk for a malformed fetus. Couples meeting the study criteria will be randomly assigned into one of two treatment groups and be immunized with either husband's cells or saline. All couples will receive TLC therapy weekly during gestational weeks 4-12, consisting of blood drawing, physical exam, ultrasound exam, and 15-20 minutes with the patient's physician. A success is considered to be achieving pregnancy within 12 months of randomization/immunization and delivering a viable offspring (greater than or equal to 28 weeks gestation). A failure is considered to be not achieving pregnancy within 12 months of randomization/immunization or experiencing a fetal loss after pregnancy is achieved. Serum samples will be stored before and weekly during the first trimester for studies of LCTA and BF. All couples achieving pregnancy and their neonate or abortus will be typed for HLA region genes using DNA probes. Comparisons between the two treatment groups will be made with respect to the following variables: 1) success rates; 2) pregnancy rates; 3) production of LCTA or BF; and 4) the presence of birth defects or chromosomal abnormalities in liveborn and abortuses, respectively. Associations between pregnancy outcome and maternal-fetal HLA status, and production of LCTA and BF will also be assessed. All analyses will consist of binomial comparisons of proportions in the two groups, corrected for continuity, or by logistic regression to assess simultaneous effects of several variables.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
1R01HD027686-01A2
Application #
3329394
Study Section
Human Embryology and Development Subcommittee 1 (HED)
Project Start
1992-08-01
Project End
1997-07-30
Budget Start
1992-08-01
Budget End
1993-07-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Aldrich, Carrie; Wambebe, Charles; Odama, Lillian et al. (2002) Linkage disequilibrium and age estimates of a deletion polymorphism (1597DeltaC) in HLA-G suggest non-neutral evolution. Hum Immunol 63:405-12
Aldrich, C; Verp, M S; Walker, M A et al. (2000) A null mutation in HLA-G is not associated with preeclampsia or intrauterine growth retardation. J Reprod Immunol 47:41-8
Ober, C; Karrison, T; Odem, R R et al. (1999) Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet 354:365-9
Ober, C; Aldrich, C L (1997) HLA-G polymorphisms: neutral evolution or novel function? J Reprod Immunol 36:1-21
Ober, C; van der Ven, K (1997) Immunogenetics of reproduction: an overview. Curr Top Microbiol Immunol 222:1-23
Ober, C; Rosinsky, B; Grimsley, C et al. (1996) Population genetic studies of HLA-G: allele frequencies and linkage disequilibrium with HLA-A1. J Reprod Immunol 32:111-23
van der Ven, K; Ober, C (1994) HLA-G polymorphisms in African Americans. J Immunol 153:5628-33
Ober, C; Steck, T; van der Ven, K et al. (1993) MHC class II compatibility in aborted fetuses and term infants of couples with recurrent spontaneous abortion. J Reprod Immunol 25:195-207
Kwak, J Y; Gilman-Sachs, A; Beaman, K D et al. (1992) Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology. J Reprod Immunol 22:15-31